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ABSTRACT 1 
Type 1 diabetes (T1D) is an autoimmune disease resulting from self-destruction of 2 
insulin-producing β cells. Reduced neutrophil counts have been observed in patients with T1D. 3 
However, the pathological roles of neutrophils in the development of T1D remain unknown. Here 4 
we show that circulating protein levels and enzymatic activities of neutrophil elastase (NE) and 5 
proteinase 3 (PR3), both of which are neutrophil serine proteases (NSPs) stored in neutrophil 6 
primary granules, were markedly elevated in patients with T1D, especially those with disease 7 
duration of less than one year. Furthermore, circulating NE and PR3 levels increased progressively 8 
with the increase of the positive numbers and titers of the autoantibodies against β-cell antigens. An 9 
obvious elevation of NE and PR3 was detected even in those autoantibody-negative patients. 10 
Increased NE and PR3 in T1D patients are closely associated with elevated formation of neutrophil 11 
extracellular traps. By contrast, the circulating levels of α1-antitrypsin (A1AT), an endogenous 12 
inhibitor of NSPs, are decreased in T1D patients. These findings support an early role of neutrophil 13 
activation and augmented NSPs activities in the pathogenesis of β-cell autoimmunity, and also 14 
suggest that circulating NE and PR3 may serve as sensitive biomarkers for diagnosis of T1D.   15 
   16 
(194 words) 17 
 18 
Key words: Autoimmune diabetes, neutrophil serine proteases, neutrophil elastase, proteinase 3, 19 
α1-antitrypsin, neutrophil extracellular traps, NETosis, biomarker 20 
 21 
 22 
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 24 
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INTRODUCTION  1 
The global incidence of type 1 diabetes (T1D), an autoimmune disease caused by an interactive 2 
combination of genetic and environmental factors, has more than doubled in the past two decades (1; 3 
2). Although the triggering factors that are involved in the initiation of T1D remain unclear, it is 4 
widely accepted that organ-specific autoimmune destruction of the insulin-producing β-cells in the 5 
pancreatic islets of Langerhans is mediated primarily by autoreactive T cells, which is accompanied 6 
by the production of different autoantibodies to β-cell antigens, including glutamic acid 7 
decarboxylase autoantibody (GADA), insulinoma-associated protein 2 autoantibody (IA2A) and 8 
zinc transporter-8 autoantibody (ZnT8A) (3-5). Although these autoantibodies have been proven to 9 
be instrumental for prediction and diagnosis of T1D, they are deemed not to be pathogenic (6; 7). A 10 
number of other immune cells, including dendritic cells (DCs), macrophages, B cells, neutrophils, 11 
are also implicated in the development of insulitis in T1D (8; 9).  12 
 13 
Neutrophils, which are the most abundant (40-75%) type of white blood cells, have recently been 14 
implicated in both the onset and progression of T1D (10; 11). The primary functions of neutrophils 15 
are to eliminate extracellular pathogens by multiple strategies, including phagocytosis, 16 
degranulation to release lytic enzymes and neutrophil extracellular traps (NETs), which are formed 17 
through a unique cell death process clearly differentiated from both apoptosis and necrosis, termed 18 
“NETosis” (12-14). On the other hand, improper activation of neutrophils may lead to tissue 19 
damage during autoimmune or exaggerated inflammatory responses (15). Notably, circulating 20 
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neutrophil counts are reduced in patients with T1D as well as their non-diabetic first-degree 1 
relatives, but not in patients with type 2 diabetes (11). In non-obese diabetic (NOD) mice (a 2 
spontaneous model of T1D), neutrophil infiltration and NET formation in the islets were observed 3 
as early as two weeks after birth, and blockage of neutrophil activities with an anti-Ly6G antibody 4 
reduces the subsequent development of insulitis and diabetes (9).  5 
 6 
Neutrophil serine proteases, including neutrophil elastase (NE), proteinase 3 (PR3) and cathepsin G 7 
(CG), are the major components of neutrophil azurophilic granules that participate in the 8 
elimination of engulfed microorganisms (16). Neutrophil activation and degranulation can result in 9 
the release of neutrophil serine proteases into the extracellular medium and circulation, where they 10 
not only help to eliminate the invaded pathogens but also serve as the humoral regulators of the 11 
immune responses during acute and chronic inflammation, modulating cellular signalling network 12 
by processing chemokines and activating specific cell surface receptors (17-19). Abnormal 13 
activities of neutrophil serine proteases have been implicated in the pathogenesis of several 14 
inflammatory and autoimmune diseases, including chronic obstructive pulmonary disease, cystic 15 
fibrosis, Wegener granulomatosis, Papillion-Lefèvre syndrome and small-vessel vasculitis (20). 16 
However, their association with T1D has not been explored so far. 17 
 18 
In this study, we measured circulating levels of two main types of neutrophil serine proteases (NE 19 
and PR3) as well as their enzymatic activities in T1D patients with different disease duration, 20 
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together with age- and sex-matched healthy controls. Furthermore, we explored whether altered 1 
NET formation and α1-antitrypsin (A1AT, a major endogenous inhibitor of neutrophil serine 2 
proteases) are associated with reduced neutrophil counts and markedly increased activities of 3 
neutrophil serine proteases in patients with T1D. In addition, we measured the dynamic changes of 4 
circulating NE/PR3 activities during the development of autoimmune diabetes in T1D. 5 
   6 
RESEARCH DESIGN AND METHODS 7 
Study cohort.  8 
One hundred and forty-nine patients with T1D were randomly selected from children diagnosed at 9 
the Diabetes Center, Second Xiangya Hospital of Central South University from October 2000 to 10 
October 2013. Patients with T1D were diagnosed according to the criteria of the American Diabetes 11 
Association (21). All patients were treated with insulin. The disease duration of T1D was 4.2 12 
(1.7-7.1) years [median (interquartile range)]. 13 
 14 
A total of 77 age- and sex-matched healthy controls were recruited from children in the community 15 
participating in health screening at the Children Health Center of the Second Xiangya Hospital, 16 
Central South University, using the following inclusion criteria: (1) fasting plasma glucose less than 17 
5.6 mmol/L and 2-h plasma glucose less than 7.8 mmol/L; (2) no family history of diabetes, and 18 
other autoimmune or chronic diseases.  19 
 20 
Page 5 of 34
For Peer Review Only
Diabetes
6 
 
A total of 25 adults with type 2 diabetes (T2D) diagnosed within one year and 25 age- and 1 
sex-matched healthy controls were recruited at the Diabetes Center, Second Xiangya Hospital of 2 
Central South University, and the inclusion criteria was described in our previous study (22). 3 
 4 
The study was approved by the Institutional Review Board of Second Xiangya Hospital of Central 5 
South University, and written informed consent was obtained from the patients and healthy controls. 6 
 7 
Clinical and biochemical assessments. 8 
After overnight fasting, a venous blood specimen was collected in the morning (around 0800 am) 9 
for analysis of various biochemical parameters. Plasma glucose was measured enzymatically on a 10 
Hitachi 7170 analyzer (Boehringer Mannheim, Mannheim, Germany). HbA1c was measured by 11 
automated liquid chromatography (Bio-Rad VARIANT II Hemoglobin Testing System, Hercules, 12 
CA, USA). Serum levels of C-peptide and C-reactive protein were quantified using a 13 
chemiluminescence immunoassay on a Bayer 180SE Automated Chemiluminescence Systems 14 
(BayerAG Leverkusen, Germany), and an immunoturbidometric assay (Orion Diagnostica, Espoo, 15 
Finland), respectively. The titers of GADA, IA2A and ZnT8A were determined by in-house 16 
radioligand assays as previously described (22; 23). 17 
 18 
Circulating protein levels of NE, PR3 and A1AT were measured using the enzyme-linked 19 
immunosorbent assay (ELISA) kits established in our laboratory (Antibody and Immunoassay 20 
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Services, the University of Hong Kong). The limits of detection for NE, PR3 and A1AT ELISA kits 1 
were 0.156 ng/ml. No cross reactivity among these proteins or with other proteins were detected. 2 
The intra- and inter-assay variations were 4.5% and 5.1%, respectively for NE ELISA kit; 3.9% and 3 
4.3%, respectively for PR3 ELISA kit; and 4.9% and 5.3%, respectively for A1AT ELISA kit.  4 
 5 
The combined enzymatic activities of PR3 and NE in serum were determined with a 6 
chromogen-based assay using N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (Sigma-Aldrich, 7 
St. Louis, MO, USA) as the substrate, which has a catalytic constant Kcat/Km of 33915 M
-1s-1 for NE 8 
and 499 M-1s-1 for PR3 (24). Briefly, 20 µl of serum was incubated with 180 µl of 0.1 M Tris-HCl 9 
buffer (pH 8.0) containing 0.5M NaCl and 1 mM substrate at 37°C for 24 hours. The amount of 10 
p-nitroaniline released was measured spectrophotometrically at 405 nm. The enzymatic activities of 11 
PR3 and NE were calculated according to the delta OD values before and after 24-hour incubation 12 
with substrate and expressed as mU/ml serum, where one unit was defined as the amount of PR3 13 
and NE that hydrolyze the substrate to yield 1 µmol of p-nitroaniline per minute at 37°C (25).  14 
 15 
The levels of neutrophil NETosis were measured by quantifying the amount of circulating 16 
myeloperoxidase (MPO)-DNA complexes, a well-established marker of NET formation as 17 
previously described (26). Briefly, 5 µg/ml of mouse anti-MPO monoclonal antibody (ABD Serotec, 18 
Germany) was coated to 96-well microtiter plates overnight at 4°C. After blocking with 1% BSA, 19 
serum samples were added per well in combination with the peroxidase-labeled anti-DNA 20 
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monoclonal antibody (component No.2 of the Cell Death Detection ELISA PLUS kit, Roche 1 
Diagnostics, USA) according to the manufacturer´s instructions. After two hours of incubation at 2 
room temperature on a shaking device (300 rpm), the wells were washed three times and then 3 
incubated with the peroxidase substrate at 37°C for 60 minutes. The optical density (OD) at 4 
wavelength of 405 nm was measured using a µQuant microplate reader (Biotek Instruments, USA). 5 
 6 
Animal studies. 7 
NOD/ShiLtJ breeder mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). 8 
BALB/c and C57BL/6N mice were obtained from the Animal Unit of the University of Hong Kong. 9 
All mice were housed in a room under specific pathogen–free conditions and 12-hour light-dark 10 
cycles at 22 to 24°C, with ad libitum access to water and standard chow (PicoLab Rodent Diet 20, 11 
LabDiet). Blood was collected weekly from female mice from 2 to 30 weeks of age. Blood glucose 12 
was monitored using an Accu-Chek Advantage glucose meter (Roche Diagnostics, USA) and 13 
diabetes was defined as two consecutive readings above 11.1 mmol/L (9). Circulating NE/PR3 14 
enzymatic activities were measured as described above. All experimental procedures were approved 15 
by the Committee on the Use of Live Animals for Teaching and Research of the University of Hong 16 
Kong and were carried out in accordance with the Guide for the Care and Use of Laboratory 17 
Animals. 18 
 19 
Statistical analysis. 20 
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All analyses were performed with Statistical Package for Social Sciences version 16.0 (SPSS, 1 
Chicago. IL). Normality was tested using the Kolmogorov-Smirnov test. Data that were not 2 
normally distributed were logarithmically transformed before analysis. Differences between groups 3 
were assessed by χ2 or unpaired t test. Comparisons among groups were performed using one-way 4 
ANOVA and independent t-tests. Correlations were analyzed using Pearson correlation or partial 5 
correlation as appropriate. Data were expressed as mean ± SD or median with interquartile range as 6 
appropriate. In all statistical comparisons, a p value < 0.05 was used to indicate a statistically 7 
significant difference.  8 
 9 
RESULTS 10 
Subject characteristics.  11 
The clinical characteristics of T1D patients and their healthy controls were described in Table 1. 12 
T1D patients were further divided into three groups based on their disease duration, including 13 
patients within 1 year from diagnosis (n=28), with a disease duration >1 and <5 years (n=59) and 14 
with duration >5 years (n=62). Compared with healthy subjects, T1D patients had higher fasting 15 
glucose and HbA1c, but lower fasting C-peptide levels. No significant differences in C-reactive 16 
protein were found among these groups (Table 1). Consistent with the previous reports (10; 11), the 17 
circulating neutrophils were moderately reduced in T1D patients diagnosed within 1 year compared 18 
with the healthy controls [median (interquartile range) (x 106/ml), 2.27 (1.80-3.52) vs 3.63 19 
(3.02-4.15), p<0.05], but not in T1D patients with a disease duration >1 and <5 years, or with 20 
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duration >5 years (Table 1). 1 
 2 
Circulating protein levels and enzymatic activities of NE and PR3 are dramatically increased 3 
in T1D patients. 4 
In contrast to the mild reduction of peripheral neutrophils, we found that the circulating protein 5 
levels of both NE and PR3 were dramatically increased in T1D patients compared to the healthy 6 
controls [NE: 1594.7 (988.4-2284.6) vs 397.0 (262.2-468.8) ng/ml, p<0.001; PR3: 295.3 7 
(206.0-430.4) vs 107.4 (92.5-165.0) ng/ml, p<0.001]. Notably, the magnitude of increases in protein 8 
levels of NE and PR3 was significantly higher in T1D patients diagnosed within 1 year as compared 9 
to the other two groups of patients with longer disease duration (all p<0.01, Fig. 1A and 1B). There 10 
were no differences in circulating protein levels of NE and PR3 between men and women in 11 
patients or controls. 12 
 13 
To further confirm the above findings, we measured the combined enzymatic activities of NE and 14 
PR3 using a common substrate, N-methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (24). The 15 
results showed that circulating NE/PR3 enzymatic activities in T1D patients were also substantially 16 
higher than those in healthy individuals [0.69 (0.41-1.03) vs 0.14 (0.10-0.21) mU/ml, p<0.001]. 17 
Likewise, the most significant increase in NE/PR3 enzymatic activities was observed in T1D 18 
patients within 1 year from diagnosis (Fig. 1C). The correlation coefficient between NE/PR3 19 
enzymatic activities and circulating protein levels was 0.915 (p<0.001) for NE and 0.874 (p<0.001) 20 
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for PR3.  1 
 2 
Circulating A1AT levels are decreased in T1D patients. 3 
The activities of plasma NE and PR3 are tightly controlled by their associated endogenous 4 
inhibitors, especially A1AT, an archetype member of the serine protease inhibitor (SERPIN) 5 
superfamily. Since our data showed that the amplitude of increases in NE/PR3 enzymatic activities 6 
was higher than that of the circulating protein levels, we next investigated whether dysregulated 7 
A1AT contributed to the increased enzymatic activities of NE and PR3 in T1D. In contrast to 8 
elevated NE and PR3 levels, the circulating concentrations of A1AT in T1D patients diagnosed 9 
within one year were significantly decreased compared to healthy subjects [1.37 (1.07-1.83) vs 1.80 10 
(1.57-2.07) mg/ml, p<0.01], whereas the decline in patients with disease duration for 1-5 years or 11 
with disease duration >5 years did not reach statistical significance (Fig. 1D).  12 
    13 
Neutrophil NETosis is increased in T1D patients 14 
To explore the underlying mechanism responsible for the markedly elevated circulating NE and 15 
PR3 levels, we examined the levels of neutrophil NETosis by quantifying the amount of circulating 16 
MPO-DNA complexes, a well-established marker of NET formation (26). In line with the increased 17 
NE and PR3 levels, a significant elevation of circulating MPO-DNA complexes was observed in 18 
T1D patients, especially in T1D patients with the disease duration of less than one year, compared 19 
to the healthy individuals [0.197 (0.049-0.412) vs 0.026 (0.011-0.058) (mean OD405), p<0.001] 20 
Page 11 of 34
For Peer Review Only
Diabetes
12 
 
(Fig. 2A). Furthermore, the amount of MPO-DNA complexes in serum was significantly correlated 1 
with the circulating protein levels of NE (r=0.554, p<0.001) and PR3 (r=0.575, p<0.001), as well as 2 
NE/PR3 enzymatic activities (r=0.527, p<0.001) (Fig 2B-2D), suggesting that the increased 3 
circulating NE and PR3 protein levels in T1D patients are at least in part attributed to enhanced 4 
neutrophil NETosis. 5 
 6 
Circulating NE and PR3 are associated with the numbers and titers of autoantibodies in T1D 7 
patients 8 
We next explored the relationship between circulating neutrophil serine proteases and the three 9 
autoantibodies associated with β-cell autoimmunity in T1D patients, including GADA, IA2A and 10 
ZnT8A. Among 149 T1D patients, 54 (36%) were autoantibody-negative, 61 (41%), 24 (16%), and 11 
10 (7%) had one, two and three autoantibodies-positive, respectively. Notably, circulating levels of 12 
both NE and PR3 proteins as well as their enzymatic activities were increased progressively with 13 
increased numbers of the autoantibodies detected in these patients (Figure 3A-3C). Even for the 14 
autoantibody-negative T1D patients, the circulating protein levels and enzymatic activities of both 15 
NE and PR3 were much higher than those in healthy controls [protein levels: NE: 1154.90 16 
(770.8-1749.5) vs 397.0 (262.2-468.8) ng/ml, p<0·0001; PR3: 237.4 (154.3-307.1) vs 107.4 17 
(92.5-165.0) ng/ml, p<0·0001; enzymatic activities: 0.53 (0.37-0.79) vs 0.14 (0.10-0.21) mU/ml, 18 
p<0.001] (Fig. 3A-3C). Furthermore, a strong correlation between the titers of GADA and the 19 
circulating protein levels of NE (r=0.296, p=0.011) and PR3 (r=0.270, p=0.021) as well as NE/PR3 20 
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enzymatic activities (r=0.275, p=0.019) were detected in T1D patients with GADA-positive (n=73) 1 
(Fig. 3D-3F). Likewise, the titers of IA2A in T1D patients with IA2A-positive (n=44) were also 2 
positively associated with the protein levels of NE, PR3 and their enzymatic activities 3 
(supplementary Fig.1A-1C). After adjustment for disease duration, the circulating protein levels and 4 
enzymatic activities of both NE and PR3 were still significantly correlated with the numbers and 5 
titers of these autoantibodies (all p<0.05, supplementary Table 1). On the contrary, no significant 6 
correlation between fasting blood glucose and circulating protein levels of NE (r=-0.103, p=0.211) 7 
or PR3 (r=-0.097, p=0.237) or NE/PR3 enzymatic activities (r=-0.078, p=0.342) was observed in 8 
the present study cohort. We further measured and compared the circulating protein levels and 9 
enzymatic activities of NE and PR3 in 25 T2D patients within 1 year from diagnosis and 25 age- 10 
and sex-matched healthy controls (supplementary Table 2). The results showed that there was no 11 
significant difference in either protein levels or enzymatic activities of NE and PR3 or NETosis 12 
between the two groups (supplementary Table 2). Taken together, these data suggested that elevated 13 
NE and PR3 may be closely associated with β-cell autoimmunity, but not glycemic status in T1D 14 
patients.   15 
 16 
Elevated NE/PR3 enzymatic activity is closely associated with the development of diabetes in 17 
NOD mice. 18 
To further explore the relationship between neutrophil serine proteases and the development of T1D, 19 
we determined the dynamic changes of PR3 and NE in NOD mice (n=30), a well-established 20 
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animal model for autoimmune diabetes from 2 to 30 weeks of age. These mice were then 1 
retrospectively assigned to two groups: those that eventually developed diabetes (n=22, called 2 
“diabetic”) and those that did not (n=8, called “non-diabetic”). In diabetic mice, the circulating 3 
NE/PR3 enzymatic activities were markedly elevated by 4 folds as early as 4 weeks after birth 4 
compared to those in 2-week-old mice, and such an elevation sustained for over 10 weeks before 5 
the onset of diabetes. Afterwards, the NE/PR3 activities in diabetic mice were gradually decreased 6 
to the baseline levels, presumably due to the termination of autoimmune responses as a result of 7 
complete β-cell destruction (Fig. 4A). In non-diabetic mice, although there was a transient and 8 
modest increase of circulating NE/PR3 activities between 4 and 5 weeks after birth (Fig. 4B), the 9 
magnitude and duration of NE/PR3 elevation was substantially lower than in age-matched diabetic 10 
mice (Fig. 4C). In BALB/c and C57BL/6N mice which do not develop insulitis and autoimmune 11 
diabetes, circulating NE/PR3 activities remained little changed throughout the 30-week observation 12 
period (Supplementary Fig. 2A-2B).  13 
 14 
DISCUSSION  15 
In this study, we demonstrated that a modest reduction of neutrophil counts in patients with T1D at 16 
onset is accompanied by a marked elevation of both protein levels and enzymatic activities of the 17 
two major neutrophil serine proteases NE and PR3. Furthermore, these changes in T1D patients are 18 
closely associated with increased neutrophil NETosis, as determined by quantification of 19 
MPO-DNA complexes in the circulation. These findings suggest that the reduction of neutrophil 20 
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counts in T1D patients is attributed in part to augmented NETosis, which in turn leads to increased 1 
NET formation and release of NE and PR3 into the blood stream.  2 
 3 
We showed that the amplitude of elevation in circulating NE/PR3 enzymatic activities and NET 4 
formation in patients with the disease duration of less than one year is substantially higher than 5 
those with disease duration of more than one year. A significant reduction in neutrophil counts is 6 
observed only in T1D patients with disease duration of less than one year. Consistent with our 7 
findings, a previous study in Italy also found that neutrophil reduction is greatest in individuals with 8 
the highest risk of developing T1D (11). After the disease onset, mild neutropenia persists for a few 9 
years and then resolves at 5 years after diagnosis (as determined by a longitudinal analysis). In 10 
NOD mice with spontaneous development of autoimmune diabetes, neutrophil infiltration and NET 11 
formation in the islets are detected as early as two weeks after birth, well before the onset of overt 12 
diabetes (9). Furthermore, neutrophil depletion at the early stage reduces subsequent development 13 
of diabetes in NOD mice (9). Taken together, these data support an early role of neutrophil NETosis, 14 
NET formation and augmented release of neutrophil serine proteases in the onset of β-cell 15 
autoimmunity in T1D. Indeed, increased neutrophil NETosis and NET formation have been 16 
implicated in a number of autoimmune diseases, including small vessel vasculitis (SVV), systemic 17 
lupus erythematosus (SLE), and multiple sclerosis (26-28).  18 
 19 
In SLE, NETs has been demonstrated to stimulate plasmacytoid DCs (pDCs) for releasing IFN-α, 20 
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which in turn augments the autoreactivity of both antigen-presenting and antibody-producing cells 1 
(29; 30). NETosis leads to the release of intracellular proteins, including histones and high mobility 2 
group protein B1, the latter of which is implicated in initiation and/or perpetuation of autoimmunity 3 
in several types of autoimmune disorders, including T1D (30; 31). Furthermore, NETs is associated 4 
with altered patterns of epigenetic and posttranslational modifications, such as methylation, 5 
acetylation and citrullination, which may represent an important source of autoantigens promoting 6 
the generation of autoantibodies (32). In particular, a growing body of evidence supports a 7 
pathogenic role for citrullinated autoantigens in triggering autoimmune responses in SLE, 8 
rheumatoid arthritis and multiple sclerosis (33). However, the pathophysiological roles of NETosis 9 
and its associated changes in T1D remain elusive.  10 
 11 
The current etiopathological diagnosis of autoimmune T1D heavily relies on the detection of the 12 
autoantibodies against several β-cell antigens. However, in children these autoantibodies are rarely 13 
detectable before six months of age (34). Moreover, the diagnostic sensitivity of the single 14 
autoantibody measurement in T1D patients is as low as 59%-67% (35). To capture the therapeutic 15 
window for this disease, it is critically important to identify new biomarkers for detection of early 16 
immunological events that affect human islets. Our current study demonstrated approximately 17 
4-fold increase of circulating protein levels and more than 5-fold elevation of enzymatic activities 18 
of NE and PR3 in T1D patients. Furthermore, elevated NE and PR3 are significantly associated 19 
with the positive numbers and titers of the autoantibodies detected in T1D patients. Even in those 20 
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autoantibody-negative patients, the circulating enzymatic activities of NE and PR3 are still 1 
substantially higher than healthy controls. Using the animal model of T1D, we found that elevated 2 
circulating NE/PR3 activities occur well before the onset of hyperglycemia and diabetes, and their 3 
activities gradually decline after the development of overt diabetes. Taken together, our data suggest 4 
that circulating NE and PR3 may serve as sensitive biomarkers for early detection of those 5 
individuals with high risk of developing T1D. On the other hand, we found no significant 6 
association between increased levels of NE and PR3 and the severity of hyperglycemia in T1D 7 
patients. In fact, while hyperglycemia becomes more severe with the progression of T1D, 8 
circulating levels of NE and PR3 exhibit opposite changes, suggesting that increased neutrophil 9 
NETosis and augmented release of NE and PR3 are not the consequence of impaired glycemic 10 
controls, but are related to β-cell autoimmunity. Indeed, our observation that NETosis and NE/PR3 11 
levels in T1D patients with longer disease duration are much lower than newly-onset patients (<1 12 
year) may be attributed to the gradual attenuation of β-cell autoimmunity with the progression of 13 
diabetes to an advanced stage. This is also in line with the fact that the number of autoantibodies in 14 
newly-onset T1D patients was much higher than those with longer disease duration (36). 15 
 16 
In addition to its classical roles for host defence against infection, neutrophil serine proteases are 17 
important regulator of inflammation and innate immunity (17; 19; 37; 38). Both NE and PR3 are 18 
involved in maturation and release of pro-inflammatory cytokines such as TNFα, IL-1β and IL-18, 19 
and also induces expression and activation of Toll-like receptors (39-42), all of which are important 20 
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mediator of insulitis and β cell destruction (43; 44). Furthermore, NE and PR3 play an 1 
indispensable role in recruiting neutrophils to the site of inflammation. Notably, neutrophil serine 2 
proteases have recently been implicated in high fat diet-induced obesity, inflammation and 3 
macrophage infiltration in adipose tissues in mice (45). Injection of recombinant PR3 alone is 4 
sufficient to induce hyperglycemia in mice (46). By contrast, treatment with A1AT, a major 5 
endogenous inhibitor of NE and PR3, decreases lymphocyte infiltration in the islets, and prevents β 6 
cell loss and diabetes in rodent models of T1D (47; 48). These animal studies, in conjunction with 7 
our clinical findings, suggest that elevated NE and PR3 may be the direct contributors to the 8 
pathogenesis of autoimmune diabetes by early involvement of autoimmune inflammatory responses 9 
in pancreatic islets.  10 
 11 
A1AT, the most abundant circulating serpin secreted from hepatocytes, inhibits neutrophil serine 12 
proteases by covalent binding to the enzymes (49). Deficiency of A1AT has been implicated in a 13 
number of inflammatory disorders such as chronic obstructive pulmonary disease (50). Our present 14 
study observed a modest, but significant reduction of circulating A1AT in patients with T1D, 15 
suggesting that augmented circulating NE and PR3 activities may result from a combination of 16 
increased release of these two enzymes from neutrophil NETosis and decreased production of their 17 
endogenous inhibitor A1AT.  18 
 19 
Our study has several limitations, including the relatively small sample size and the cross-sectional 20 
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design. In addition, since our samples were collected from Chinese only, whether or not the findings 1 
are replicable in other ethnic group remains to be determined. Further large scale, longitudinal 2 
studies on different ethnic groups are mandatory to clarify the roles of NE and PR3 in the initiation 3 
and progression of β-cell autoimmunity, and to evaluate their clinical value for prediction and early 4 
diagnosis of T1D.  5 
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Figure Legends 1 
FIG.1. Circulating protein levels of NE (A) and PR3 (B), NE/PR3 enzymatic activities (C), and 2 
A1AT protein levels (D) in healthy controls (n=77), T1D patients within 1 year from diagnosis 3 
(n=28), with a disease duration >1 and <5 years from diagnosis (n=59) and with duration >5 years 4 
(n=62) from diagnosis are shown as box plots. The horizontal line in the middle of each box 5 
indicates the median value; the top and bottom borders of the boxes represent the 75th and 25th 6 
percentiles, respectively; the whiskers represent the 10th and 90th percentiles, and the dots 7 
represent the outliers. ** p<0.01, *** p<0.001 vs Healthy controls; # p<0.05, ## p<0.01 vs T1D 8 
patients within 1 year from diagnosis.  9 
  10 
FIG. 2. Circulating levels of MPO-DNA complexes in healthy controls (n=77), T1D patients within 11 
1 year from diagnosis (n=28), with a disease duration >1 and <5 years (n=59) and with duration >5 12 
years (n=62) (A). Circulating MPO-DNA complexes were significantly correlated with circulating 13 
NE (B) and PR3 (C) protein levels, and enzymatic activities of both NE and PR3 (D). ** p<0.01, 14 
*** p<0.001 vs Healthy controls; ## p<0.01 vs T1D patients within 1 year from diagnosis.  15 
 16 
FIG. 3. Circulating protein levels of NE (A) and PR3 (B), enzymatic activities of both NE and PR3 17 
(C) in healthy controls (n=77), T1D patients with autoantibody negative (n=54), one 18 
autoantibody-positive of GADA, IA2A or ZnT8A (n=61), two autoantibodies-positive of GADA, 19 
IA2A or ZnT8A (n=24), or three autoantibodies-positive of GADA, IA2A and ZnT8A (n=10). 20 
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Circulating protein levels of NE (D) and PR3 (E), and enzymatic activities of both NE and PR3 (F) 1 
were significantly correlated with the titers of GADA in T1D patients with GADA-positive (n=73). 2 
*** p<0.001 vs Healthy controls; # p<0.05, ## p<0.01, ### p<0.001 vs T1D patients with autoantibody 3 
negative; $ p<0.05 vs T1D patients with one autoantibody-positive.  4 
 5 
FIG. 4. Dynamic changes in enzymatic activities of circulating NE/PR3 in NOD female mice. 6 
Blood samples were collected weekly from 30 NOD female mice from 2 to 30 weeks after birth. 7 
Circulating NE/PR3 enzymatic activities along with their blood glucose levels were measured in 8 
mice that developed diabetes (n=22, A) and that remained non-diabetic (n=8, B) until 30 weeks 9 
after birth. (C) Comparisons of NE/PR3 enzymatic activities between diabetic mice and 10 
non-diabetic mice throughout the observation period. # p<0.05 vs the NE/PR3 enzymatic activities 11 
at 2 weeks of age; * p<0.05 vs age-matched non-diabetic mice. 12 
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TABLE 1  
Characteristics of healthy controls and T1D patients recruited for this study 
  Healthy controls 
T1D patients from diagnosis 
< 1 year 1 - 5 years > 5 years 
n 77 28 59 62 
Age (years) 13.3 ± 5.3 15.4 ± 6.9 12.9 ± 4.3 14.9 ± 3.8 
Sex (men/women) 43/34 12/16 21/38 24/38 
BMI (kg/m2) 18.35 ± 2.70 17.56 ± 3.16 17.83 ± 3.77 18.46 ± 3.05 
Duration of diabetes (years) N/A 0.4 (0.2-0.7) 2.8 (1.9-3.9) 7.6 (6.4-9.3) 
Fasting glucose (mmol/L)§ 4.69 (4.41-4.89) 7.85 (6.20-11.93)a 8.4 (6.60-14.20)a 7.80 (5.68-11.83)a 
HbA1c (%)§ 5.00 (4.80-5.15) 8.05 (6.03-11.15)a 7.50 (6.70-10.10)a 7.40 (6.48-8.43)a 
(mmol/mol)§ 31 (29-33) 64 (42-99)a 58 (50-87)a 57 (47-69)a 
Fasting C-peptide (pmol/L)§ 445.4 (362.1-678.2) 55.35 (16.92-146.73)a 22.80 (5.50-92.95)a,b 5.50 (4.20-28.43)a,b,c 
C reactive protein (mg/L)§ 0.23 (0.13-0.61) 0.24 (0.11-0.51) 0.27 (0.13-0.75) 0.28 (0.15-1.12) 
Blood cell counts 
    
Erythrocytes ( x 106/ml)§ 4.66 (4.30-4.94) 4.52 (4.06-5.12) 4.83 (4.54-5.17) 4.82 (4.50-5.03) 
White blood cells ( x 106/ml)§ 6.85 (5.80-7.78) 4.70 (3.75-7.35)a 5.70 (4.95-6.90) 6.40 (5.20-6.97) 
Lymphocytes ( x 106/ml)§ 2.18 (1.55-2.62) 1.74 (1.57-2.08) 1.98 (1.54-2.43) 1.84 (1.64-2.38) 
Monocytes ( x 106/ml)§ 0.42 (0.34-0.49) 0.29 (0.17-0.37)a 0.29 (0.22-0.38)a 0.31 (0.23-0.39)a 
Neutrophils ( x 106/ml)§ 3.63 (3.02-4.15) 2.27 (1.80-3.52)a 3.29 (2.75-4.15) 3.49 (3.02-4.14) 
Eosinophils ( x 106/ml)§ 0.20 (0.12-0.34) 0.13 (0.08-0.20)a 0.15 (0.12-0.23) 0.15 (0.11-0.21) 
Basophils ( x 106/ml)§ 0.05 (0.03-0.06) 0.03 (0.02-0.07) 0.07 (0.05-0.10)a,b 0.08 (0.06-0.14)a,b 
Platelets ( x 106/ml)§ 256 (223-315) 244 (202-285)a 219 (193-265)a 250 (199-280) 
Date are expressed as mean ± SD or median (interquartile range) as appropriate. 
§Log transformed before analysis. aCompared with healthy controls, p < 0.05; bcompared with T1D patients from diagnosis < 1 years, p < 0.05; ccompared 
with T1D patients from diagnosis 1 - 5 years, p < 0.05. 
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FIG.1. Circulating protein levels of NE (A) and PR3 (B), NE/PR3 enzymatic activities (C), and A1AT protein 
levels (D) in healthy controls (n=77), T1D patients within 1 year from diagnosis (n=28), with a disease 
duration >1 and <5 years from diagnosis (n=59) and with duration >5 years (n=62) from diagnosis are 
shown as box plots. The horizontal line in the middle of each box indicates the median value; the top and 
bottom borders of the boxes represent the 75th and 25th percentiles, respectively; the whiskers represent 
the 10th and 90th percentiles, and the dots represent the outliers. ** p<0.01, *** p<0.001 vs Healthy 
controls; # p<0.05, ## p<0.01 vs T1D patients within 1 year from diagnosis.  
149x121mm (300 x 300 DPI)  
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FIG. 2. Circulating levels of MPO-DNA complexes in healthy controls (n=77), T1D patients within 1 year from 
diagnosis (n=28), with a disease duration >1 and <5 years (n=59) and with duration >5 years (n=62) (A). 
Circulating MPO-DNA complexes were significantly correlated with circulating NE (B) and PR3 (C) protein 
levels, and enzymatic activities of both NE and PR3 (D). ** p<0.01, *** p<0.001 vs Healthy controls; ## 
p<0.01 vs T1D patients within 1 year from diagnosis.  
149x129mm (300 x 300 DPI)  
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FIG. 3. Circulating protein levels of NE (A) and PR3 (B), enzymatic activities of both NE and PR3 (C) in 
healthy controls (n=77), T1D patients with autoantibody negative (n=54), one autoantibody-positive of 
GADA, IA2A or ZnT8A (n=61), two autoantibodies-positive of GADA, IA2A or ZnT8A (n=24), or three 
autoantibodies-positive of GADA, IA2A and ZnT8A (n=10). Circulating protein levels of NE (D) and PR3 (E), 
and enzymatic activities of both NE and PR3 (F) were significantly correlated with the titers of GADA in T1D 
patients with GADA-positive (n=73). *** p<0.001 vs Healthy controls; # p<0.05, ## p<0.01, ### 
p<0.001 vs T1D patients with autoantibody negative; $ p<0.05 vs T1D patients with one autoantibody-
positive.  
152x204mm (300 x 300 DPI)  
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FIG. 4. Dynamic changes in enzymatic activities of circulating NE/PR3 in NOD female mice. Blood samples 
were collected weekly from 30 NOD female mice from 2 to 30 weeks after birth. Circulating NE/PR3 
enzymatic activities along with their blood glucose levels were measured in mice that developed diabetes 
(n=22, A) and that remained non-diabetic (n=8, B) until 30 weeks after birth. (C) Comparisons of NE/PR3 
enzymatic activities between diabetic mice and non-diabetic mice throughout the observation period. # 
p<0.05 vs the NE/PR3 enzymatic activities at 2 weeks of age; * p<0.05 vs age-matched non-diabetic mice. 
113x201mm (300 x 300 DPI)  
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Supplementary Table 1  
Correlations of circulating protein levels and enzymatic activities of NE and PR3 with 
clinical parameters in T1D patients 
  
Circulating NE protein levels 
 
Circulating NE protein levels 
(Diabetes duration-adjusted) 
  r p r p 
Diabetes duration (years) -0.203 0.017 — — 
Fasting glucose (mmol/L)* -0.103 0.211 -0.106 0.200 
HbA1c (%)* 0.083 0.315 0.069 0.405 
Fasting C-peptide (pmol/L)* 0.151 0.066 0.125 0.130 
Neutrophils ( x 10
6
/ml)* 0.108 0.189 0.101 0.213 
Numbers of autoantibodies-positive 0.427 <0.001 0.415 <0.001 
GADA tirers*
a
 0.296 0.011 0.313 0.007 
IA2A titers*
b
 0.422 0.004 0.403 0.007 
ZnT8A titers*
c
 0.205 0.360 0.201 0.380 
    
  
Circulating PR3 protein levels 
 
Circulating PR3 protein levels 
(Diabetes duration-adjusted) 
  r p r p 
Duration of diabetes (years) -0.212 0.010 — — 
Fasting glucose (mmol/L)
*
 -0.097 0.237 -0.102 0.214 
HbA1c (%)* 0.140 0.090 0.120 0.145 
Fasting C-peptide (pmol/L)* 0.158 0.052 0.120 0.145 
Neutrophils ( x 10
6
/ml)
*
 0.074 0.368 0.065 0.470 
Numbers of autoantibodies-positive 0.428 <0.001 0.411 <0.001 
GADA tirers*
a
 0.270 0.021 0.279 0.018 
IA2A titers*
b
 0.486 0.001 0.450 0.002 
ZnT8A titers*
c
 0.288 0.194 0.285 0.209 
    
  
NE/PR3 enzymatic activities 
 
NE/PR3 enzymatic activities 
(Diabetes duration-adjusted) 
  r p r p 
Duration of diabetes (years) -0.196 0.021 — — 
Fasting glucose (mmol/L)
*
 -0.078 0.342 -0.080 0.334 
HbA1c (%)* 0.101 0.219 0.093 0.260 
Fasting C-peptide (pmol/L)* 0.151 0.066 0.137 0.098 
Neutrophils ( x 10
6
/ml)
*
 0.128 0.119 0.107 0.198 
Numbers of autoantibodies-positive 0.403 <0.001 0.397 <0.001 
GADA tirers*
a
 0.275 0.019 0.280 0.017 
IA2A titers*
b
 0.389 0.009 0.386 0.011 
ZnT8A titers*
c
 0.193 0.390 0.190 0.409 
*Log transformed before analysis; 
 a. include only subjects with GADA-positive (n = 73); b. include only subjects with IA2A-positive (n = 
44); c. include only subjects with ZnT8A-positive (n = 22).  
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Supplementary Table 2 
Circulating protein levels and enzymatic activities of NE and PR3, A1AT protein levels, 
and MPO-DNA complexes in T2D patients and their healthy controls 
  Healthy controls T2D patients p value 
n 25 25 - 
Age (years) 47.8 ± 5.7 48.0 ± 6.0 0.815 
Sex (men/women) 12/13 12/13 1.000 
BMI (kg/m
2
) 20.45 ± 2.57 26.37 ± 3.45
a
 <0.001 
Duration of diabetes (years) N/A 0.4 (0.1-0.7) - 
Fasting glucose (mmol/L)
§
 4.86 (4.59-5.36) 7.62 (6.29-9.35)
a
 <0.001 
HbA1c (%)
§
 5.24 (5.02-5.51) 7.45 (6.46-8.70)
a
 <0.001 
(mmol/mol)
§
 34 (31-37) 58 (48-72)
a
 <0.001 
C reactive protein (mg/L)
§
 0.47 (0.24-0.86) 1.82 (1.03-4.37)
a
 <0.001 
Blood cell counts    
Erythrocytes ( x 10
6
/ml)
§
 4.72 (4.38-5.43) 4.79 (4.45-5.66) 0.877 
White blood cells ( x 10
6
/ml)
§
 5.91 (5.23-7.46) 6.68 (4.62-7.93) 0.014 
Lymphocytes ( x 10
6
/ml)
§
 2.11 (1.59-2.66) 3.08 (1.59-3.92)
a
 0.017 
Monocytes ( x 10
6
/ml)
§
 0.38 (0.24-0.49) 0.39 (0.19-0.51) 0.796 
Neutrophils ( x 10
6
/ml)
§
 3.42 (2.94-4.71) 3.54 (3.07-4.83) 0.487 
Eosinophils ( x 10
6
/ml)
§
 0.15 (0.08-0.21) 0.16 (0.10-0.22) 0.864 
Basophils ( x 10
6
/ml)
§
 0.03 (0.01-0.07) 0.04 (0.02-0.0.07) 0.763 
Platelets ( x 10
6
/ml)
§
 225 (176-279) 228 (187-295) 0.824 
Circulating NE protein levels (ng/ml) 403.7 (255.4-482.1) 411.5 (268.3-512.7) 0.377 
Circulating PR3 protein levels (ng/ml) 109.3 (87.4-174.5) 113.7 (76.4-201.3) 0.413 
Circulating NE/PR3 enzymatic 
activities (mU/ml) 
0.16 (0.11-0.34) 0.18 (0.11-0.40) 0.428 
Circulating A1AT protein levels 
(mg/ml) 
1.70 (1.42-2.11) 1.63 (1.37-2.05) 0.275 
MPO-DNA complexes (mean OD405) 0.030 (0.011-0.057) 0.033 (0.015-0.064) 0.439 
    
Date are expressed as mean ± SD or median (interquartile range) as appropriate. 
 
§
Log transformed before analysis. 
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Supplementary Figure. 1.  
Circulating protein levels of NE (A) and PR3 (B), and NE/PR3 enzymatic activities (C) 
were significantly correlated with the titers of IA2A in T1D patients with IA2A-positive 
(n=44).  
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Supplementary Figure. 2.  
Dynamic changes of circulating NE/PR3 enzymatic activities along with their blood 
glucose levels in BALB/c (n=10, A) and C57BL/6 mice (n=10, B) from 2 to 30 weeks of 
age.  
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